Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | CA2 | P00918 | 2/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | CA9 | Q16790 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1820807 | 0.90 | CA12 (0.69) | KMT2AMEN1CA1CA2CA12 | |
| SCHEMBL6490406 | 0.86 | CA1 (0.68) | KMT2AMEN1CA1CA2CA12 | |
| SCHEMBL5192269 | 0.84 | KMT2A (0.74) | KMT2AMEN1CA1CA2CA12 | |
| SCHEMBL4022887 | 0.84 | KMT2A (0.87) | KMT2AMEN1CA1CA2CA12 | |
| SCHEMBL3348400 | 0.84 | CA1 (0.69) | KMT2AMEN1CA1CA2CA12 | |
| SCHEMBL248400 | 0.84 | CA1 (0.79) | KMT2AMEN1CA1CA2CA12 | |
| SCHEMBL9051137 | 0.84 | CA1 (0.69) | KMT2AMEN1CA1CA2CA12 | |
| SCHEMBL30738251 | 0.84 | CA1 (0.79) | KMT2AMEN1CA1CA2CA12 | |
| SCHEMBL6484083 | 0.84 | KMT2A (0.62) | KMT2AMEN1CA1CA2CA12 | |
| SCHEMBL23392535 | 0.83 | MAPT (0.77) | KMT2AMEN1CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064714-A1 | Novel Pyrrolodihydroisoquinolines | NYCOMED GMBH (DE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064714-A1 | Novel Pyrrolodihydroisoquinolines | MKI67, BAD, BAX | KMT2A 1708/4885MEN1 3740/4885CA1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.